| Document |
Document Title |
|
JP2011523971A |
Compounds of the formula (I), wherein R1, R2 and R3 for example are hydrogen, halogen, CN, C1-C18alkyl, C1-C10 haloalkyl, (CO)R8, (CO)OR4, or (CO)NR5R6; Y is O, S or CO; D2, D3 and D4 for example are a direct bond, O, S, NR7, CO, O(CO), ...
|
|
JP4745609B2 |
The invention provides non-steroidal ligands for the glucocorticoid receptor, methods for making non-steroidal ligands of the glucocorticoid receptor, compositions of non-steroidal ligands of the glucocorticoid receptor and methods of us...
|
|
JP4744356B2 |
To produce a synthetic intermediate product of a raw monomer for a short-side-chain perfluorosulfonate polymer superior in heat resistance, with a simple process and at a high yield. This production method is a method for producing a com...
|
|
JP4727994B2 |
A fungicidally active compound of formula (1): where Het is a substituted 5- or 6-membered heterocyclic ring; R1 is hydrogen, formyl, CO-C1-4 alkyl, COO-C1-4 alkyl, C1-4 alkoxy(C1-4)alkylene, CO-C1-4 alkylenoxy(C1-4)alkyl, propargyl or a...
|
|
JP4722829B2 |
This invention relates to novel oxathiincarboxamides of the formula (I) in which G1, G2, G3, n, R1, R2, R3, R4, R5 and Z are as defined in the disclosure, to a plurality of processes for preparing these compounds and their use for contro...
|
|
JP2011516591T |
the organic materials which have the remarkable stability over the decomposition induced by oxidization, heat, or light and/or to which it may reduce the surface energy of organic materials -- formula (I) -- at least one sort of compound...
|
|
JP4682248B2 |
The present invention provides a method for producing a sulfonate ester efficiently and in high yield. The present invention is an invention of a method for producing a sulfonate ester compound, which comprising reacting: (a) a compound ...
|
|
JP2011075827A |
To provide an actinic ray-sensitive or radiation-sensitive resin composition excellent in sensitivity, resolution, roughness property, pattern configuration, temporal stability and outgassing property, and to provide a pattern forming me...
|
|
JP4663324B2 |
Compounds of formula (I): wherein the substituents are as defined herein.
|
|
JP2011052211A |
To provide a method for manufacturing a photoresist composition capable of forming a resist pattern having excellent characteristics, a compound providing such a photoresist composition, resin and resist pattern.The compound is expressed...
|
|
JP4653966B2 |
A process produces a 2-benzoyloxyacetaldehyde derivative represented by following Formula (3): wherein R1 and R2 may be the same as or different from each other and are each a hydrocarbon group, wherein R1 and R2 may be combined to form ...
|
|
JP2011507949A |
Provided is a pharmaceutical composition for the treatment and prevention of kidney diseases, containing (a) a therapeutically effective amount of a compound represented by Formulae 1 or 2 or a pharmaceutically acceptable salt, prodrug, ...
|
|
JP2011507948A |
Provided is a pharmaceutical composition for the treatment and prevention of cardiac diseases, containing (a) a therapeutically effective amount of a compound represented by Formula 1 or 2 or a pharmaceutically acceptable salt, prodrug, ...
|
|
JP2011011982A |
To provide an industrially advantageous method for safely producing, in a good yield, a 1,3-benzoxathiin-4-one 1-oxide compound which is a raw material compound for a 1,2-benzoisothiazolin-3-one compound useful as an industrial antimicro...
|
|
JP4607591B2 |
The invention relates to a fungicidally active compound of formula (I): where Het is a 5- or 6-membered heterocyclic ring containing one to three heteroatoms, each independently selected from oxygen, nitrogen and sulphur, provided that t...
|
|
JP4597667B2 |
The present invention relates to new Macro-cycles of Formula (I), and their use for the treatment of cancer.
|
|
JP4590045B2 |
|
|
JP4588407B2 |
|
|
JP4583598B2 |
The purification and structure elucidation of several products of the metabolism of Et 743 by human cytochrome CYP3A4 have been accomplished. These compounds are abbreviated herein as "ETM" followed by a numeric value which represents th...
|
|
JP2010237277A |
To provide a photomask blank which has high sensitivity and is superior in storage stability and safelight aptitude, and a photomask which has high resolution and is superior in linearity of image edge parts. The photomask blank has, on ...
|
|
JP4557159B2 |
A chemically amplified positive resist composition comprising a specific 2,4,6-triisopropylbenzenesulfonate compound as a photoacid generator, a polymer which changes its solubility in an alkaline developer under the action of acid, and ...
|
|
JP2010215656A |
To provide related structures having the same or higher level antitumor activities than conspicuous antitumor activities of the ecteinascidin (Et) 743 compound.Compounds having structural formula of the figure have the same or higher lev...
|
|
JP4554219B2 |
The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for t...
|
|
JP4555085B2 |
Alkoxyimino-substituted biphenylcarboxamide derivatives (I) are new. Akoxyimino-substituted biphenylcarboxamide derivatives of formula (I) are new. R = hydrogen, 1-6C alkyl or 1-3C haloalkyl containing 1-7 fluoro, chloro and/or bromo; Z ...
|
|
JP4547913B2 |
A carboxylic acid compound represented by formula (I): (meanings of the symbols in the formula are as mentioned in the specification) and a pharmaceutical agent comprising the compound. Since the compound represented by formula (I) b...
|
|
JP4542776B2 |
A process for producing predominantly cis nucleosides or nucleoside analogues and derivates of formula (A): wherein R1 is a pyrimidine base or a pharmaceutically acceptable derivative thereof and Q is oxygen, carbon or sulphur, comprisin...
|
|
JP4536987B2 |
The present invention relates to a compound of the formula (I) wherein R1 is an unsubstituted or substituted hydrocarbon radical having a total of 1 to 10 carbon atoms, preferably 1 to 6 carbon atoms, R2 is an unsubstituted or substitute...
|
|
JP2010168328A |
To provide a compound having excellent control effect on harmful arthropods.The N-phenylimine compound is represented by formula (1) [wherein G is phenyl which may be substituted with (X2)q or the like; X is -S-R1 or the like; X0 is -S-R...
|
|
JP4510919B2 |
This invention is directed to compounds useful as intermediates in the synthesis of lipoxin A4 analogs of the following formulas (I) and (II): wherein R1, R2, R3, R4 and R5 are described herein. These analogs are useful in treating infla...
|
|
JP4511191B2 |
A compound of formula (I): Het is pyridinyl, pyrimidinyl, thiophenyl, furyl, isothiazolyl or isoxazolyl, each being substituted by groups R 4 , R 5 and R 6 ; R 1 is hydrogen or halo; R 2 is hydrogen or halo; R 3 is optionally substituted...
|
|
JP4508531B2 |
3-(arylthiopropylamino)-1,5-aryloxathiepine derivatives (I) are new. 3-(arylthiopropylamino)-1,5-aryloxathiepine derivatives of formula (I) and their (hydrated) addition salts with (in)organic acids, tautomers, enantiomers and stereoisom...
|
|
JP4504570B2 |
The present invention relates to a class of carbocyclic compounds of Formula I that are useful as potassium channel inhibitors to treat autoimmune disorders, cardiac arrhythmias, and the like.
|
|
JP4503206B2 |
A method and composition for the treatment of humans infected with HIV that includes administration of an HIV treatment amount of an enantiomerically pure beta -D-dioxolanyl purine nucleoside of formula (I), wherein R is OH, Cl, NH2, or ...
|
|
JP4496377B2 |
The present invention relates to a method of preparing BCH-189 and various analogues of BCH-189 from inexpensive precursors with the option of introducing functionality as needed. This synthetic route allows the stereoselective preparati...
|
|
JP2010132672A |
To provide a method for treating or preventing obesity, diabetes, anxiety, depression, neurodegeneration, or inflammatory diseases. There are provided a nonsteroidal ligand for glucocorticoid receptors, a method for producing a nonsteroi...
|
|
JP2010520884A |
This invention is directed to, for example, compounds of formula (I): wherein n, m, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically accep...
|
|
JP2010519277A |
A compound of general formula (I): A process for preparing this compound. A fungicidal composition comprising a compound of general formula (I). A method for treating plants by applying a compound of general formula (I) or a composition ...
|
|
JP2010120947A |
To provide a commercial method for producing a sulfite compound of high purity at a high yield, useful as an intermediate or a raw material for synthesizing an unprocessed pharmaceutical/agrochemical compound, an electronic material, or ...
|
|
JP4471928B2 |
|
|
JP4460843B2 |
|
|
JP4461863B2 |
To provide a method for industrially producing a sulfite compound, by which the sulfite compound useful as a synthetic intermediate or a raw material for medicine technical products, agrochemical technical products, electronic materials,...
|
|
JP4449907B2 |
There is provided a lithium secondary battery which has excellent characteristics such as energy density and electromotive force and is excellent in cycle life and storage stability. An electrolyte solution for secondary battery comprisi...
|
|
JP2010510984A |
Disclosed is a pharmaceutical composition for the treatment and/or prevention of erectile dysfunction, comprising (a) a therapeutically effective amount of a compound represented by Formula 1 or 2, and (b) a pharmaceutically acceptable c...
|
|
JP2010510982A |
Disclosed is a pharmaceutical composition for the treatment and/or prevention of erectile dysfunction, comprising (a) a therapeutically effective amount of a compound represented by Formula 1 or 2, and (b) a pharmaceutically acceptable c...
|
|
JP2010510980A |
Disclosed is a pharmaceutical composition for the treatment and/or prevention of erectile dysfunction, comprising (a) a therapeutically effective amount of a compound represented by Formula 1 or 2, and (b) a pharmaceutically acceptable c...
|
|
JP2010510983A |
Disclosed is a pharmaceutical composition for the treatment and/or prevention of erectile dysfunction, comprising (a) a therapeutically effective amount of a compound represented by Formula 1 or 2, and (b) a pharmaceutically acceptable c...
|
|
JP4432311B2 |
To provide purified ethylene sulfite which is stable when used as the component of an electrolysis solution. The production method of the purified ethylene sulfite comprises a step of purifying crude ethylene sulfite, which is obtained b...
|
|
JP4431853B2 |
The invention concerns drug precursors with antimalarial effect, characterised in that it consists in quaternary bis-ammonium salts of general formula (I) wherein A and A', identical or different, are respectively either a group A1 and A...
|
|
JP4427281B2 |
|
|
JP4384536B2 |
To obtain a new anthracene compound suitably useful as a luminescent material for an organic electroluminescent element and an organic electroluminescent element using the anthracene compound. The anthracene compound is represented by fo...
|
